openPR Logo
Press release

Global Fibroblast Growth Factor Receptor FGFR Cancer Therapy Market Clinical Trials Insight 2026

11-19-2021 11:52 AM CET | Health & Medicine

Press release from: Kuick Resarch

Global Fibroblast Growth Factor Receptor FGFR Cancer Therapy

Global Fibroblast Growth Factor Receptor Inhibitor Drug Market Opportunity and Clinical Trials Insight 2026 Report Highlights:

• Global FGFR Inhibitors Market Opportunity: > USD 4 Billion by 2026
• Role of FGFR Inhibitors in Cancer Therapy
• Global FGFR Market Assessment (US$) by Region and Cancer Type
• Clinical and Sales Insight on Approved FGFR Inhibitors: 3 (Belvesra, Pemazyre and Truseltiq)
• Dosage and Drug Price Insight on Approved FGFR Inhibitors
• Comprehensive Clinical Trials Insight by Company, Country, Phase and Patient Segment: 53 Drugs in Trials

Download Report

https://www.kuickresearch.com/report-fibroblast-growth-factor-receptor-market-size-sales-companies-insight-growth-clinical-trials-balversa-erdafitinib-truseltiq-pemigatinib-pemazyre-infigratinib-human-fgfr1-fgfr2-fgfr3-pathway-cancer-mutation-fda-approved-fgfr-inhibitor

Fibroblast growth factor receptor (FGFR) belongs to the family of receptor tyrosine kinases, and consists of five members (FGFR1-5) that share remarkable sequence homology. The FGFR signaling pathway is closely related to the occurrence of embryogenesis, angiogenesis, tissue homeostasis, and wound repair. In addition, it also plays critical role in cell proliferation, differentiation, apoptosis, and migration. Any alterations in this pathway lead to a variety of diseases, especially malignant tumors, which are caused by gene amplification, mutation, and gene fusion. Therefore, the identification of alerted FGFR provides new opportunity to develop novel targeted therapy in the management of cancer.

Balversa (erdafitinib) developed by Janssen Pharmaceuticals is the first FGFR kinase inhibitor to receive FDA approval for the management of patients with locally advanced or metastatic urothelial carcinoma, with susceptible FGFR3 or FGFR2 genetic alterations, that has progressed during or following platinum-containing chemotherapy. The drug is targeted kinase inhibitor that exerts its action by binding to and blocking the enzymatic activity of several cell proteins, including FGFR1, FGFR2, FGFR3, and FGFR4. In addition, erdafitinib binds to other proteins, including FLT4, KIT, VEGFR2, RET, CSF1R, and PDGFRA, which further enhances its efficiency in the management of cancer. The entrance of the drug in the market has shown encouraging sales owing to its high specificity and targetability.

The promising results of Balversa in the market have further led to approval of two other FGFR inhibitors in the market. In 2020, Pemazyre (pemigatinib) developed by Incyte Corporation was approved for adults with certain types of previously treated, advanced cholangiocarcinoma. Recently in 2021, Truseltiq (infigratinib) developed by QED Therapeutics has gained approval for adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma. Although the market is poised to growth in coming years but several factors limits their growth in market. The high cost of cancer therapy is one of the major limiting factors which will restrict the growth of market in coming years.

Presently, several companies including well-established players and new entrants are actively engaged in developing FGFR inhibitors for a wide range of disease indications. Innovation in this field is mostly focused on improving the therapeutic efficacy, safety, and overall survival rate. The pipeline for FGFR inhibitor is highly crowded and consists of several players including AZD4547, E7090, Futibatinib, Derazantinib, CPL304110, and several others. Major Key players in the market have entered into strategic alliances including collaboration or partnerships which will further propel the growth of market. For instance, AZD4547 is being developed in collaboration of Burning Rock Biotech Limited with Abbisko Therapeutics.

As per our analysis, the global FGFR inhibitor market is expected to reach US$ XX Billion by 2026. The rising geriatric population and subsequent increase in the prevalence of cancer is one of the major driving factors in the market. In addition, rising initiative by government and robust research and development by several pharmaceutical giants will also drive the growth of market. The leading pharmaceutical companies working in this sector are Amgen, Astem pharma, AstraZeneca, Bayer, BMS, Incyte, Roche, Taiho, Janssen pharmaceuticals, Novartis etc. while many other companies are working on FGFR inhibitors in preclinical studies. Further, US will lead FGFR market due to availability of huge cancer burden and leading pharmaceutical companies.

The report global FGFR inhibitor market profoundly explores the recent significant development by the leading vendors and innovation profiles. The report provides in-depth information about commercial information of the approved drugs and further analyzes their penetration in the market till 2028. Based on Indication, the market was studied across cholangiocarcinoma, urothelial cancer, lymphoma, and lung cancer. Based on region, the market was studied across US, Europe, Japan, and rest of world.

Contact:
Neeraj Chawla
Research Head
neeraj@kuickresearch.com
+91-9810410366

India

Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Global Fibroblast Growth Factor Receptor FGFR Cancer Therapy Market Clinical Trials Insight 2026 here

News-ID: 2468164 • Views: 189

More Releases from Kuick Resarch

Global Orphan Drug Rare Disease Market Clinical Trials Forecast 2028
Global Orphan Drugs Clinical Trials Insight Report Highlights: • Clinical Insight On More Than 400 Marketed Orphan Drugs • Clinical Insight On More Than 1300 Orphan Drugs in Clinical Trials • Orphan Designated Drug Clinical Status by Indication & Country • Global Market Opportunity More Than USD 350 Billion • Market Exclusivity & Patent Protection Criteria for Orphan Drugs • Global & Regional Orphan Drug Market Sales Opportunity • Orphan Drug Reimbursement Policy • Orphan Clinical Pipeline Overview
Global CD233 Antibody Market Clinical Trials Intelligence 2028
Global CD233 Inhibitors Trials Intelligence Report Highlights: • Global CD233 Inhibitors Market Dynamics • Clinical Approaches to Target CD233 Inhibitors • Role of CD233 Inhibitors in Cancer, Autoimmune Disorders • Number of CD233 Inhibitors Drug In Trials • CD233 Inhibitors Approved Patent Insight • CD233 Inhibitors Trials By Phase, Company, Country, Indication • Company Agreement/Partnership/Deals For Ongoing Trials • Global CD233 Inhibitor Market Future Outlook For Report Sample Contact neeraj@kuickresearch.com The successful application of the anti-CTLA-4 and anti-PD-1/PD-L1
Global Gene Therapy Market Clinical Trials Research Insight 2028
Global Gene Therapy Market & Clinical Trials Intelligence Report Highlights • Global Market Gene Therapy Landscape USD 24 Billion Opportunity • Comprehensive Commercial & Clinical insight on 16 Approved Gene Therapies • Gene Therapy Products Dosage & Price Analysis • Comprehensive Clinical Insight On 1700 Gene Therapies In Clinical Trials • Information On 45 Orphan Designated Gene Therapies By Indication, Country, Company • Global Gene Therapy Clinical Trials Insight By Phase, Country, Formulations, Company, Indication, Target •
TROP2 Targeted Therapy Trodelvy Market Clinical Trials Insight 2026
Global TROP2 Antibody Market & Clinical Trials Insight 2026 Report Analysis and Data Highlights: • Research Methodology • Global & Regional Market Analysis • Global TROP2 Antibody Market Opportunity Assessment: > USD 4 Billion • Market and Drug Sales Insight 2020 Till 2026 • Approved Drug In Market: 1 Drugs • Approved TROP2 Antibody Patent, Price and Sales insight 2020 Till 2026 • Future Market Assessment By Indication Till 2026 • Ongoing Clinical Trials Assessment by Status, Phase & Region • Key Market Dynamics • Competitor Landscape Download Report:

All 5 Releases


More Releases for FGFR

"NSCLC - Market Outlook and Competitive Landscape Report 2015 – 2030 "
Report Snapshot: NSCLC is the most common form of lung cancer, accounting for approximately 85% of all types and subtypes of lung cancer. It grows and spreads more slowly than small cell lung cancer. Early stage disease is associated with uncommon specific symptoms; hence roughly ~50% to 73% of cases are not being diagnosed until the disease is at an advanced stage when the chances for cure or significant patient benefit
Hepatocellular Carcinoma Disease Pipeline Drugs Assessment: Clinical Trails Anal …
Hepatocellular Carcinoma Disease Pipeline Drugs Assessment Overview: Hepatocellular Carcinoma is the most common primary tumour of liver. It is caused to the people who are having underlying liver diseases such as hepatitis B or C virus, Cirrhosis and non – alcoholic fatty liver disease. HCC does not cause any symptoms in the early stages of diseases. Some of the symptoms of HCC includes loss of appetite, weight loss, nausea and
Urothelial Carcinoma Treatment Market: Global Market Estimation, Dynamics, Regio …
Market Outline: Global Urothelial Carcinoma Treatment Market Urothelial carcinoma is also called as transitional cell carcinoma. Urothelial carcinoma is a type of cancer that occurs in the urinary system and it is most common type of bladder cancer of the ureter, urachus and urethra. Urothelial cell carcinoma starts from transitional epithelium. Potential signs in recognising the urothelial carcinoma include blood in urine, persistent back pain and painful urination. Generally, urothelial cell
Tyrosine Kinase Inhibitors - Pipeline Insights 2017
The “Tyrosine kinase Inhibitors-Pipeline Insights 2017″ report provides a comprehensive analysis of tyrosine kinase inhibitor drug candidates currently undergoing clinical trials. It covers detailed drug profiles of potential Akt inhibitors across various clinical development phases including–discovery, pre-clinical, IND, Phase I, Phase II, Phase III and pre-registration. The report also includes the pipeline products’ clinical trial data along with information on other development activities, including technology, licensing, collaborations, acquisitions, funding, patent,
Download Global Cancer Tyrosine Kinase Inhibitors Market & Clinical Pipeline Out …
The global increase in the prevalence of cancer and the increasing recognition of the therapeutic and commercial opportunities offered by new oncology treatments has provided a major incentive for the pharmaceutical industry to pursue the development of new agents for the treatment of cancer. To tackle the ever rising global cancer burden, the cancer treatment is inclining towards the targeted drug therapy due to the numerous drawbacks associated with conventional
Global Cancer Tyrosine Kinase Inhibitors Market & Clinical Pipeline Outlook 2020
The global increase in the prevalence of cancer and the increasing recognition of the therapeutic and commercial opportunities offered by new oncology treatments has provided a major incentive for the pharmaceutical industry to pursue the development of new agents for the treatment of cancer. To tackle the ever rising global cancer burden, the cancer treatment is inclining towards the targeted drug therapy due to the numerous drawbacks associated with conventional